RS66090B1 - Kombinovana terapija sa sorafenibom ili regorafenibom i fosforamidatnim prolekom troksacitabina - Google Patents
Kombinovana terapija sa sorafenibom ili regorafenibom i fosforamidatnim prolekom troksacitabinaInfo
- Publication number
- RS66090B1 RS66090B1 RS20241192A RSP20241192A RS66090B1 RS 66090 B1 RS66090 B1 RS 66090B1 RS 20241192 A RS20241192 A RS 20241192A RS P20241192 A RSP20241192 A RS P20241192A RS 66090 B1 RS66090 B1 RS 66090B1
- Authority
- RS
- Serbia
- Prior art keywords
- troxacitabine
- phosphoramidate prodrug
- sorafenib
- cancer
- use according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1650274 | 2016-03-02 | ||
| SE1651204 | 2016-09-08 | ||
| EP17760400.6A EP3423061B1 (en) | 2016-03-02 | 2017-02-28 | Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine |
| PCT/SE2017/050186 WO2017151044A1 (en) | 2016-03-02 | 2017-02-28 | Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS66090B1 true RS66090B1 (sr) | 2024-11-29 |
Family
ID=59744330
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20241192A RS66090B1 (sr) | 2016-03-02 | 2017-02-28 | Kombinovana terapija sa sorafenibom ili regorafenibom i fosforamidatnim prolekom troksacitabina |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10456413B2 (https=) |
| EP (1) | EP3423061B1 (https=) |
| JP (1) | JP6968080B2 (https=) |
| KR (1) | KR102703122B1 (https=) |
| CN (2) | CN111956646B (https=) |
| AU (2) | AU2017227516B2 (https=) |
| CA (1) | CA3014769C (https=) |
| ES (1) | ES2987989T3 (https=) |
| HR (1) | HRP20241508T1 (https=) |
| HU (1) | HUE068940T2 (https=) |
| MY (1) | MY198140A (https=) |
| PL (1) | PL3423061T3 (https=) |
| RS (1) | RS66090B1 (https=) |
| RU (1) | RU2018134336A (https=) |
| SG (1) | SG11201806855WA (https=) |
| WO (1) | WO2017151044A1 (https=) |
| ZA (1) | ZA201805445B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3014769C (en) * | 2016-03-02 | 2024-01-09 | Medivir Aktiebolag | Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine |
| EP3747433A4 (en) | 2018-02-02 | 2021-12-22 | Cafa Therapeutics Limited | COMBINATION OF CELL IMMUNOTHERAPY |
| JP7337539B2 (ja) | 2018-06-21 | 2023-09-04 | メディヴィル・アクチエボラーグ | 白血病療法のための塩基修飾シチジンヌクレオチド |
| CN113453685A (zh) * | 2019-02-18 | 2021-09-28 | 美迪维尔公司 | 使用口服给药的二氧戊环核苷酸与抗pd1或抗pdl1单克隆抗体的组合治疗肝癌的方法 |
| HUE071473T2 (hu) * | 2020-04-15 | 2025-09-28 | Medivir Ab | MIV-818/lenvatinib kombinációs terápia májrák kezelésére |
| KR20210156389A (ko) | 2020-06-17 | 2021-12-27 | 재단법인대구경북과학기술원 | 레고라페닙을 유효성분으로 포함하는 염증질환의 예방 또는 치료용 약학적 조성물 |
| IT202000022636A1 (it) | 2020-09-25 | 2022-03-25 | Ente Ospedaliero Specializzato In Gastroenterologia Istituto Nazionale Di Ricovero E Cura A Caratter | “terapia di combinazione di sorafenib e/o regorafenib con la proteina ricombinante umana proteoglicano-4 per il trattamento dell'epatocarcinoma” |
| TW202444368A (zh) * | 2023-03-30 | 2024-11-16 | 瑞典商米迪維艾克提伯拉公司 | 以氟曲沙他濱布洛帕胺(fostroxacitabine bralpamide)、免疫檢查點抑制劑及vegf拮抗劑治療肝癌之方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| EP1158985B1 (en) | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
| AU2002212015B2 (en) * | 2000-10-13 | 2007-01-25 | Shire Canada Inc. | Dioxolane analogs for improved inter-cellular delivery |
| US7235576B1 (en) | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| EP1636585B2 (en) | 2003-05-20 | 2012-06-13 | Bayer HealthCare LLC | Diaryl ureas with kinase inhibiting activity |
| EP1663978B1 (en) * | 2003-07-23 | 2007-11-28 | Bayer Pharmaceuticals Corporation | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| US20090098137A1 (en) * | 2006-04-05 | 2009-04-16 | Novartis Ag | Combinations of therapeutic agents for treating cancer |
| US8728516B2 (en) * | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
| CN102190616B (zh) | 2010-03-18 | 2015-07-29 | 苏州泽璟生物制药有限公司 | 一种氘代的ω-二苯基脲的合成及生产的方法和工艺 |
| SG10201608579UA (en) | 2012-04-13 | 2016-12-29 | Epizyme Inc | Combination therapy for treating cancer |
| CN103570613B (zh) | 2012-07-18 | 2016-06-15 | 苏州泽璟生物制药有限公司 | 氘代ω-二苯基脲或其盐的多晶型物 |
| JP6342392B2 (ja) | 2012-07-28 | 2018-06-13 | カリター・サイエンシーズ・エルエルシー | 置換型ピラゾロン化合物及び使用方法 |
| WO2014047199A1 (en) * | 2012-09-19 | 2014-03-27 | The Research Foundation For The State University Of New York | Novel prodrugs for selective anticancer therapy |
| CN105934438A (zh) * | 2013-11-27 | 2016-09-07 | 艾登尼克斯药业有限公司 | 用于治疗肝癌的核苷酸 |
| EP3074399A1 (en) * | 2013-11-27 | 2016-10-05 | Idenix Pharmaceuticals LLC | 2'-dichloro and 2'-fluoro-2'-chloro nucleoside analogues for hcv infection |
| NZ729118A (en) * | 2014-08-25 | 2022-02-25 | Medivir Ab | Dioxolane analogues of uridine for the treatment of cancer |
| CA3014769C (en) | 2016-03-02 | 2024-01-09 | Medivir Aktiebolag | Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine |
-
2017
- 2017-02-28 CA CA3014769A patent/CA3014769C/en active Active
- 2017-02-28 WO PCT/SE2017/050186 patent/WO2017151044A1/en not_active Ceased
- 2017-02-28 CN CN202010727607.5A patent/CN111956646B/zh active Active
- 2017-02-28 ES ES17760400T patent/ES2987989T3/es active Active
- 2017-02-28 PL PL17760400.6T patent/PL3423061T3/pl unknown
- 2017-02-28 RU RU2018134336A patent/RU2018134336A/ru not_active Application Discontinuation
- 2017-02-28 MY MYPI2018703064A patent/MY198140A/en unknown
- 2017-02-28 RS RS20241192A patent/RS66090B1/sr unknown
- 2017-02-28 HU HUE17760400A patent/HUE068940T2/hu unknown
- 2017-02-28 KR KR1020187028361A patent/KR102703122B1/ko active Active
- 2017-02-28 JP JP2018545847A patent/JP6968080B2/ja active Active
- 2017-02-28 CN CN201780014430.0A patent/CN109069509B/zh active Active
- 2017-02-28 AU AU2017227516A patent/AU2017227516B2/en active Active
- 2017-02-28 HR HRP20241508TT patent/HRP20241508T1/hr unknown
- 2017-02-28 US US16/081,383 patent/US10456413B2/en active Active
- 2017-02-28 EP EP17760400.6A patent/EP3423061B1/en active Active
- 2017-02-28 SG SG11201806855WA patent/SG11201806855WA/en unknown
-
2018
- 2018-08-15 ZA ZA2018/05445A patent/ZA201805445B/en unknown
-
2019
- 2019-08-30 US US16/557,511 patent/US10960017B2/en active Active
-
2022
- 2022-06-01 AU AU2022203761A patent/AU2022203761B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022203761B2 (en) | Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine | |
| Shabir et al. | Chemistry and pharmacology of fluorinated drugs approved by the FDA (2016–2022) | |
| WO2017037292A1 (en) | Combination of a dhodh inhibitor and a her inhibitor for use in the treatment of cancer | |
| CN106255756A (zh) | 肝癌的索拉非尼‑微rna联合疗法 | |
| AU2021255043B2 (en) | MIV-818/lenvatinib combination therapy for liver cancer | |
| Ng et al. | Sorafenib (BAY 43-9006): review of clinical development | |
| HK40040637A (en) | Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine | |
| HK40040637B (zh) | 索拉非尼或瑞戈非尼与曲沙他滨的氨基磷酸酯前药的组合治疗 | |
| HK40000353B (en) | Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine | |
| HK40000353A (en) | Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine | |
| CN103961709A (zh) | 组蛋白甲基转移酶抑制剂与化疗剂组合在治疗肿瘤中的用途 | |
| BR112018067387B1 (pt) | Uso de um agente terapêutico | |
| HK40081068A (en) | Miv-818/lenvatinib combination therapy for liver cancer | |
| CN101837128B (zh) | 含有索拉非尼、mek抑制剂与egfr酪氨酸激酶抑制剂的药物组合物及其应用 | |
| Khan et al. | b. Systemic therapy |